Drug treatments for obesity: Difference between revisions
imported>Mark Cairns |
imported>Neil R. J. Watson |
||
| Line 26: | Line 26: | ||
By Neil R. J. Watson | By Neil R. J. Watson | ||
<ref>Authors names, "The perfect review for part 3," Publishers City (2009)</ref> | <ref>Authors names, "The perfect review for part 3," Publishers City (2009)</ref> | ||
One method of pharmaceutically tackling obesity is to give cannabinoid receptor type 1 (CB1 receptor) antagonists such as rimonabant. Mice genetically engineered to be deficient in CB-1 receptors have been shown to be resistant to diet induced obesity. Numerous clinical trials have demonstrated weight loss in obese subjects, as well as improving the ratio of good (HDL) to bad (LDL) cholesterol. However, a major issue in using CB1 antagonists is the incidence of psychiatric problems, in particular, depression (unfortunately several suicides occured during trials). As a result, the FDA has not approved the use of rimonabant in the United States. The European Medicines Agency (EMEA) has recommended the marketing authorisation of rimonabant be suspended across the EU, and consequently NICE has withdrawn its guidance for the use of the drug. | |||
http://eurheartj.oxfordjournals.org/cgi/reprint/ehn255v1.pdf | |||
http://www.nice.org.uk/TA144 | |||
==Peripheral Drugs== | ==Peripheral Drugs== | ||
Revision as of 09:31, 6 October 2009
This page was started in the framework of an Eduzendium course and needs to be assessed for quality. If this is done, this {{EZnotice}} can be removed.
A brief overview of your interest group (be sure to put its name in bold in the first sentence) and the scope of the article goes here.[1]
The following list of sections should serve as a loose guideline for developing the body of your article. The works cited in references 2-5 are all fake; their purpose is to serve as a formatting model for your own citations.
Introduction
History
In here you could write about various informations linked to various references for example from journals. [2] [3]
Limited Efficacy
You can also insert diagram.
Serotonin & Noradrenaline Related Drugs
By Bruce McLintock [4]
Endocannabinoids
By Neil R. J. Watson [5]
One method of pharmaceutically tackling obesity is to give cannabinoid receptor type 1 (CB1 receptor) antagonists such as rimonabant. Mice genetically engineered to be deficient in CB-1 receptors have been shown to be resistant to diet induced obesity. Numerous clinical trials have demonstrated weight loss in obese subjects, as well as improving the ratio of good (HDL) to bad (LDL) cholesterol. However, a major issue in using CB1 antagonists is the incidence of psychiatric problems, in particular, depression (unfortunately several suicides occured during trials). As a result, the FDA has not approved the use of rimonabant in the United States. The European Medicines Agency (EMEA) has recommended the marketing authorisation of rimonabant be suspended across the EU, and consequently NICE has withdrawn its guidance for the use of the drug.
http://eurheartj.oxfordjournals.org/cgi/reprint/ehn255v1.pdf
http://www.nice.org.uk/TA144
Peripheral Drugs
By Rachael Kirkbride
Everything Else
Metformin
Off Label Use...
Caffeine
By Mark Cairns
Conclusion
We are the best. YALDI!
References
- ↑ See the "Writing an Encyclopedia Article" handout for more details.
- ↑ First Author and Second Author, "The perfect reference for Subpart 1," Fake Journal of Neuroendocrinology 36:2 (2015) pp. 36-52.
- ↑ First Author and Second Author, "Another perfect reference for Subpart 1," Fake Journal of Neuroendocrinology 25:2 (2009) pp. 62-99.
- ↑ "Part 2," Appetite and obesity. 2006. Retrieved July 21, 2009 from http://www.appetiteandobesity.org/part2.html
- ↑ Authors names, "The perfect review for part 3," Publishers City (2009)